Effects of propofol on the outcomes of rats with sepsis

Journal of Surgical Research

Volumn 168, Issue 1, 2011, Pages

  Bao, Hong Guang ^a   Li, Sha ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

high mobility group box 1; propofol; sepsis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; PROPOFOL; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFECT; LUNG PARENCHYMA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SEPSIS; SURVIVAL; UREA NITROGEN BLOOD LEVEL;

ANESTHETICS, INTRAVENOUS; ANIMALS; CECUM; DISEASE MODELS, ANIMAL; HEART; HMGB1 PROTEIN; INJECTIONS, INTRAVENOUS; KIDNEY; LIGATION; LIVER; LUNG; MALE; PROPOFOL; RATS; RATS, WISTAR; SEPSIS; TREATMENT OUTCOME;

EID: 79955604882     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.12.034     Document Type: Article

References (17)

1. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546.
2. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997;25:1115.
3. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-α MAb Sepsis Study Group. JAMA 1995;273:934.
4. Bustin M. Regulation of DNA dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237.
5. Wang H, Yang H, Tracey KJ.HMGB1as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768.
6. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149.
7. Taniguchi T, Kanakura H, Yamamoto K. Effects of posttreatment with propofol on mortality and cytokine responses to endotoxin-induced shock in rats. Crit Care Med 2002;30:904.
8. Weiss YG, Bellin L, Kim PK, et al. Compensatory hepatic regeneration after mild, but not fulminant, intraperitoneal sepsis in rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G968.
9. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248.
10. Shao YM, Yao HG, Liang HZ, et al. Relation between level of expression of high mobility group protein B1 in hepatic tissue with the severity and prognosis of sepsis in rats. Chin Crit Care Med 2006;18:668.
11. McGuinness OP, Lacy DB, Ejiofor J, et al. Hepatic release of tumor necrosis factor in the endotoxin-treated conscious dog. Shock 1996;5:344.
12. Gao J, Zeng BX, Zhou LJ, et al. Protective effects of early treatment with propofol on endotoxin-induced acute lung injury in rats. Br J Anaesth 2004;92:277.
13. Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197.
14. Song XM, Wang YL, Li JG, et al. Effects of propofol on proinflammatory cytokines and nuclear factor kB during polymicrobial sepsis in rats. Mol Biol Rep 2009;36:2345.
15. Mathy-Hartert M, Mouithys-Mickalad A, Kohnen S, et al. Effects of propofol on endothelial cells subjected to a peroxynitrite donor(SIN-1). Anaesthesia 2000;55:1066.
16. Hsu BG, Yang FL, Lee RP, et al. Effects of post-treatment with low-dose propofol on inflammatory responses to lipopolysaccharide-induced shock in conscious rats. Clin Exp Pharmacol Physiol 2005;32:24.
17. WuGJ, Chen TL, Ueng YF, et al. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol 2008;228:105.